GI INNOVATION

AACR 2026_GI-128 POSTER

Discovery and characterization of GI-128 : A PD-L1 x LILRB1/2/4 bispecific antibody as a macrophage engager
AACR 2026_GI-102 POSTER

Prediction of pharmacokinetic and pharmacodynamic profile for a fixed dosing and body weight-based dosing of GI-102 based on cell-level pharmacodynamics-mediated drug disposition model in patients with advanced or metastatic solid tumors
ESMO 2025_GI-102 POSTER

Keynote-G08: An open-label, multicenter, dose escalation and expansion phase I/II study of GI-102 (CD80/IL2v3) in advanced solid tumors (part A and D of GII-102-P101)
SITC 2024_CAR-T POSTER

GI-101A, a Novel CD80-IgG4-IL2v2 Fusion Protein, Promotes CAR-T Expansion and Enhances Anticancer Potential by Increasing Memory T Cell Population in a Lymphoma Model
SITC 2024_GI-108 POSTER

A first-in-human, open-label, multicenter, phase 1/2a, dose-escalation and expansion study of GI-108, a novel immunocytokine combining anti-CD73-IL2v, in patients with advanced or metastatic solid tumors
ASCO 2024_GI-102 POSTER

A first-in-human, phase 1/2a study of GI-102 (CD80-IL2v3) in patients with advanced or metastatic solid tumors: Initial results from dose escalation
SITC 2023_GI-102 POSTER

GI-102, a novel CD80-IgG4-IL2v3 fusion protein driving lymphocytes expansion and anti-cancer potential through regulation of immune cells in the tumor microenvironment
2023 SITC_GI-108 POSTER

GI-108, a novel anti-CD73-IL2v bispecific fusion protein augments anti-tumor immunity by alleviating immunosuppressive adenosine pathway in CD8+ T cells
SITC 2023_Keynote-B59 POSTER

Keynote-B59: Dose escalation of a phase 1/2 first-in-human, open-label study of GI-101, a novel immunocytokine combining CD80-IL2v, in combination with pembrolizumab in advanced solid tumors
SITC 2023_GI-102 POSTER

A first-in-human, open-label, multicenter, phase 1/2a, dose escalation and expansion study of GI-102, a novel immunocytokine combining CD80-IL2v3, in patients with advanced or metastatic solid tumors

COMPANY